INFLIXIMAB, RoActemra 20 mg/mL concentrate for solution for infusion
P160909
Phase 2 small_molecule active
Quick answer
INFLIXIMAB, RoActemra 20 mg/mL concentrate for solution for infusion for Takayasu arteritis is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Takayasu arteritis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active